Several studies have revealed that miR-205 plays important roles in the development of gynecological cancers and thus may serve as a potential prognostic biomarker, but the current conclusions remain controversial. Therefore, the goal of this study was to explore the prognostic significance and functional mechanisms of miR-205 based on a meta-analysis and bioinformatics investigation. A total of 14 published studies containing 5835 patients were enrolled by searching the PubMed, EMBASE, and Cochrane library databases, 13 (14 datasets) and 5 (6 datasets) of which evaluated the correlations between the expression level of miR-205 and overall survival (OS) or disease-free survival (DFS)/disease-specific survival (DSS)/progression-free survival (PFS)/distant metastasis-free survival (DMFS), respectively. Furthermore, the use of online Kaplan–Meier plotter database analysis supplemented another seven results for OS. Then, a meta-analysis using these 21 and 6 datasets was performed. As a result, the overall analysis failed to demonstrate any significant associations between miR-205 expression and OS (p = 0.267) or DSS/DFS/DMFS/PFS (p = 0.457), but the subgroup analysis suggested that elevated miR-205 predicted a reduced OS for breast cancer (BC) patients (hazard ratio [HR] = 0.84, 95% confidence interval [CI] = 0.72–0.98; p = 0.022), while higher miR-205 was associated with a poor DSS for endometrial cancer (EC) patients (HR = 2.19, 95% CI = 1.45–3.32; p < 0.001). Function prediction analysis indicated that miR-205 may be involved in BC by negatively influencing hub genes, SMARCA5 and SIAH1, whereas miR-205 may participate in EC by negatively modulating BMPR1B because of the presence of interactions of miR-205 with them at 3′-untranslated region and their opposite prognosis outcomes with miR-205. In conclusion, our findings suggest miR-205 may be a promising prognostic biomarker and therapeutic target for BC and EC patients.
Get full access to this article
View all access options for this article.
References
1.
AdamM.G., MattS., ChristianS., Hess-StumppH., HaegebarthA., HofmannT.G., et al. (2015). SIAH ubiquitin ligases regulate breast cancer cell migration and invasion independent of the oxygen status. Cell Cycle, 14, 3734–3747.
2.
BaderG.D., and HogueC.W. (2003). An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 4, 2.
3.
ChuP., LiangA., JiangA., and ZongL. (2018). miR-205 regulates the proliferation and invasion of ovarian cancer cells via suppressing PTEN/SMAD4 expression. Oncol Lett, 15, 7571–7578.
4.
ChungT.K., CheungT.H., HuenN.Y., WongK.W., LoK.W., YimS.F., et al. (2010). Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer, 124, 1358–1365.
5.
DweepH., and GretzN. (2015). miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods, 12, 697.
6.
ElgamalO.A., ParkJ.K., GusevY., Azevedo-PoulyA.C., JiangJ., RoopraA., et al. (2013). Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One, 8, e76402.
7.
Flores-PérezA., MarchatL.A., Rodríguez-CuevasS., BautistaV.P., Fuentes-MeraL., Romero-ZamoraD., et al. (2016). Suppression of cell migration is promoted by miR-944 through targeting of SIAH1 and PTP4A1 in breast cancer cells. BMC Cancer, 16, 379.
8.
GuanB., LiQ., ShenL., RaoQ., WangY., ZhuY., et al. (2016). MicroRNA-205 directly targets Krüppel-like factor 12 and is involved in invasion and apoptosis in basal-like breast carcinoma. Int J Oncol, 49, 720–734.
9.
GultekinM., KucukyildizI., KaracaM.Z., DundarS., BoztasG., TuranS.H., et al. (2017). Trends of gynecological cancers in Turkey: toward Europe or Asia?. Int J Gynecol Cancer, 27, 1525–1533.
10.
HasegawaT., AdachiR., IwakataH., TakenoT., SatoK., and SakamakiT. (2017). ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. FEBS Open Bio, 7, 1154–1165.
11.
HigginsJ.P.T., ThompsonS.G., DeeksJ.J., and AltmanD.G. (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557–560.
12.
HuangD.W., ShermanB.T., and LempickiR.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4, 44–57.
13.
HuoL., WangY., GongY., KrishnamurthyS., WangJ., DiaoL., et al. (2016). MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol, 29, 330–346.
14.
JinC., and LiangR. (2015). miR-205 promotes epithelial-mesenchymal transition by targeting AKT signaling in endometrial cancer cells. J Obstet Gynaecol Res, 41, 1653–1660.
15.
JinQ., MaoX., LiB., GuanS., YaoF., and JinF. (2015). Overexpression of SMARCA5 correlates with cell proliferation and migration in breast cancer. Tumor Biol, 36, 1895–1902.
16.
KaraayvazM., ZhangC., LiangS., ShroyerK.R., and JuJ. (2012). Prognostic significance of miR-205 in endometrial cancer. PLoS One, 7, e35158.
17.
KimS.Y., KawaguchiT., YanL., YoungJ., QiQ., and TakabeK. (2017). Clinical relevance of microRNA expressions in breast cancer validated using The Cancer Genome Atlas (TCGA). Ann Surg Oncol, 24, 2943–2949.
18.
KohlM., WieseS., and WarscheidB. (2011). Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol, 696, 291–303.
19.
LiJ., HuK., GongG., ZhuD., WangY., LiuH., et al. (2017a). Upregulation of MiR-205 transcriptionally suppresses SMAD4 and PTEN and contributes to human ovarian cancer progression. Sci Rep, 7, 41330.
20.
LiJ.H., SunS.S., LiN., LvP., XieS.Y., and WangP.Y. (2017b). MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer. Oncotarget, 8, 91938–91949.
21.
LuZ., XuY., YaoY., and JiangS. (2019). miR-205-5p contributes to paclitaxel resistance and progression of endometrial cancer by downregulating FOXO1. Oncol Res [Epub ahead of print]; DOI: 10.3727/096504018X15452187888839.
22.
MaQ., WanG., WangS., YangW., ZhangJ., and YaoX. (2014). Serum microRNA-205 as a novel biomarker for cervical cancer patients. Cancer Cell Int, 14, 1–7.
23.
MaY.J., HaC.F., BaiZ.M., LiH.N., XiongY., and JiangJ. (2016). Overexpression of microRNA-205 predicts lymph node metastasis and indicates an unfavorable prognosis in endometrial cancer. Oncol Lett, 12, 4403–4410.
24.
MaddenS.F., ColinC., PatriciaG., AherneS.T., NormaO.D., MartinC., et al. (2013). BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res, 15, R52.
25.
MarkouA., YousefG.M., StathopoulosE., GeorgouliasV., and LianidouE. (2014). Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem, 60, 197–205.
26.
Mayoral-VaroV., CalcabriniA., Sánchez-BailónM.P., and Martín-PérezJ. (2017). miR205 inhibits stem cell renewal in SUM159PT breast cancer cells. PLoS One, 12, e0188637.
PangH., and YueX. (2017). MiR-205 serves as a prognostic factor and suppresses proliferation and invasion by targeting insulin-like growth factor receptor 1 in human cervical cancer. Tumour Biol, 39, [Epub ahead of print]; DOI: 10.1177/1010428317701308.
29.
QuesneJ.L, JonesJ., WarrenJ., DawsonS.J., AliH.R., BardwellH., et al. (2012). Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol, 227, 306–314.
30.
RadojicicJ., ZaravinosA., VrekoussisT., KafousiM., SpandidosD.A., and StathopoulosE.N. (2011). MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle, 10, 507–517.
31.
RichardsE.G., El-NasharS.A., SchoolmeesterJ.K., KeeneyG.L., MarianiA., HopkinsM.R., et al. (2016). Abnormal uterine bleeding is associated with increased BMP7 expression in human endometrium. Reprod Sci, 24, 671–681.
32.
ShamseerL., MoherD., ClarkeM., GhersiD., LiberatiA., PetticrewM., et al. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 349, g7647.
33.
SiegelR.L., MillerK.D., and JemalA. (2018). Cancer statistics, 2018. CA Cancer J Clin, 68, 7–30.
34.
SrivastavaS.K., AhmadA., ZubairH., MireeO., SinghS., RocconiR.P., et al. (2017). MicroRNAs in gynecological cancers: small molecules with big implications. Cancer Lett, 407, 123–138.
35.
StangA. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603–605.
36.
SuN., QiuH., ChenY., YangT., YanQ., and WanX. (2013). miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep, 29, 2297–2302.
37.
SzklarczykD., FranceschiniA., WyderS., ForslundK., HellerD., Huerta-CepasJ., et al. (2015). STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res, 43, D447–D452.
38.
TangY., LiM., WangJ., PanY., and WuF.X. (2015). CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks. Biosystems, 127, 67–72.
39.
TorresA., KozakJ., KorolczukA., RycakD., WdowiakP., MaciejewskiR., et al.. (2016). Locked nucleic acid-inhibitor of miR-205 decreases endometrial cancer cells proliferation in vitro and in vivo. Oncotarget, 7, 73651–73663.
40.
TorresA., TorresK., PesciA., CeccaroniM., PaszkowskiT., CassandriniP., et al. (2013). Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. Int J Cancer, 132, 1633–1645.
41.
WangL., KangF.B., WangJ., YangC., and HeD.W. (2019). Downregulation of miR-205 contributes to epithelial–mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1–RAGE signaling pathway. Anticancer Drugs, 30, 225–232.
42.
WilczynskiM., DanielskaJ., DzienieckaM., SzymanskaB., WojciechowskiM., and MalinowskiA. (2016). Prognostic and clinical significance of miRNA-205 in endometrioid endometrial cancer. PLoS One, 11, e0164687.
43.
YangX., YangL., MaY., ZhaoX., and WangH. (2017). MicroRNA-205 mediates proteinase-activated receptor 2 (PAR2)-promoted cancer cell migration. Cancer Invest, 35, 601–609.
44.
ZhangH., and FanQ. (2015). MicroRNA-205 inhibits the proliferation and invasion of breast cancer by regulating AMOT expression. Oncol Rep, 34, 2163–2170.
45.
ZhangH., LiB., ZhaoH., and ChangJ. (2015a). The expression and clinical significance of serum miR-205 for breast cancer and its role in detection of human cancers. Int J Clin Exp Med, 8, 3034–3043.
46.
ZhangJ.Y., SunM.Y., SongN.H., DengZ.L., XueC.Y., and YangJ. (2015b). Prognostic role of microRNA-205 in multiple human malignant neoplasms: a meta-analysis of 17 studies. BMJ Open, 5, e006244.
47.
ZhengH., ZhangL., ZhaoY., YangD., SongF., WenY., et al. (2013). Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One, 8, e77853.
